Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Novavax Hit $250 This Year?

TheMotleyFool

0 0

Vaccine maker Novavax (NASDAQ: NVAX) has fallen harder than the broader market of late, dropping by 36% in the past three months alone. Investors' views of the biotech have fluctuated along with news surrounding the pandemic, as well as what some of its competitors in the COVID-19 vaccine market are up to.

But despite Novavax's recent issues, Wall Street has high hopes for the stock. The company's average one-year price target currently stands at a whopping $250, according to Yahoo! Finance. Meanwhile, Novavax's shares are trading at $95.22. Can the company hit this mark within the next 12 months?